Immune checkpoint inhibitors use in liver transplantation for hepatocellular carcinoma: a global cohort study
With careful management, peri-LT ICIs may be considered for HCC patients. Optimizing washout periods and monitoring graft PD-L1 expression may improve transplant outcomes.
Authors
- Li Zhao (ORCID: https://orcid.org/0000-0002-0503-2955)
- Jiye Zhu (ORCID: https://orcid.org/0000-0003-0456-7584)
- Jialing Hao (ORCID: https://orcid.org/0000-0001-9114-3231)
- Delin Ma (ORCID: https://orcid.org/0000-0001-6886-9886)
- Wenzai Shi
- Zhuomiaoyu Chen (ORCID: https://orcid.org/0009-0001-2800-0884)
- Jie Gao (ORCID: https://orcid.org/0000-0003-0772-4530)
- Yongjing Luo
- Pengcheng Wei (ORCID: https://orcid.org/0000-0003-0002-9439)
- Zhigao Yuan
- Chen Hao Lo (ORCID: https://orcid.org/0000-0001-8848-2507)
- Zuyin Li
- Lijie Qiao (ORCID: https://orcid.org/0009-0009-1573-5812)
- Qian Cheng
Institutions
- Peking University (CN)
- Peking University People's Hospital (CN)
- Peking University International Hospital (CN)
- Aviation General Hospital (CN)
Publication Details
- Journal
- BMC Medicine
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1186/s12916-025-04352-z
- Citations
- 7
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 9.25
Funders
- National Natural Science Foundation of China
- National Science and Technology Major Project
- Capital Health Research and Development of Special Fund